Biblio

Author Title [ Type

] Year

Filters: Author is Freilone, Roberto [Clear All Filters]

Journal Article

Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, Ferrero S, Chiarenza A, Freilone R, Novo M, et al. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2021.

Levis M, Piva C, Filippi ARiccardo, Botto B, Gavarotti P, Pregno P, Nicolosi M, Freilone R, Parvis G, Gottardi D, et al. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016.

Urbino I, Secreto C, Apolito V, Olivi M, Arrigo G, Boscaro E, Catania FMaria, D'Ardia S, Frairia C, Giai V, et al. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience. Leuk Res. 2023:107421.

Olivi M, Di Biase F, Lanzarone G, Arrigo G, Martella F, Apolito V, Secreto C, Freilone R, Bruno B, Audisio E, et al. Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges. Curr Treat Options Oncol. 2023.

Apolito V, Arrigo G, Vasseur L, Olivi M, Perrone S, Giai V, Secreto C, Di Biase F, De Simone MCarla, Copia C, et al. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax. Br J Haematol. 2023.